Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

Rhea-AI Summary

Oyster Point Pharma (Nasdaq: OYST), a clinical-stage biopharmaceutical company, announced its participation in the Piper Sandler 32^nd Annual Virtual Healthcare Conference on December 3, 2020. The company focuses on first-in-class therapies for ocular surface diseases. Its lead product, OC-01 nasal spray, aims to treat dry eye disease by stimulating natural tear production through a novel mechanism that activates the trigeminal parasympathetic pathway.

PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in the Piper Sandler 32^nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020 and host investor meetings.

About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 nasal spray’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit. 

Investor Contact: 
Tim McCarthy 
LifeSci Advisors, LLC 
(212) 915-2564 
investors@oysterpointrx.com 

Media Contact: 
Sheryl Seapy, W2O Group 
(213) 262-9390 
sseapy@w2ogroup.com 

FAQ

What is the significance of the Piper Sandler 32nd Annual Virtual Healthcare Conference for OYST?

OYST will participate in this event on December 3, 2020, to discuss their developments and engage with investors.

What is OC-01 nasal spray developed by Oyster Point Pharma?

OC-01 is a nasal spray designed to treat dry eye disease by stimulating the glands responsible for natural tear production.

When is Oyster Point Pharma's participation in the conference scheduled?

Oyster Point Pharma is set to participate in the conference on December 3, 2020.

What focus area does Oyster Point Pharma specialize in?

Oyster Point Pharma specializes in the discovery and development of therapies for ocular surface diseases.